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The skeletal muscle Ca2+ release channel, also known as ryanodine receptor type 1
(RyR1), is the largest ion channel protein known and is crucial for effective skeletal
muscle contractile activation. RyR1 function is controlled by Cav1.1, a voltage gated
Ca2+ channel that works mainly as a voltage sensor for RyR1 activity during skeletal
muscle contraction and is also fine-tuned by Ca2+, several intracellular compounds (e.g.,
ATP), and modulatory proteins (e.g., calmodulin). Dominant and recessive mutations in
RyR1, as well as acquired channel alterations, are the underlying cause of various skeletal
muscle diseases. The aim of this mini review is to summarize several current aspects of
RyR1 function, structure, regulation, and to describe the most common diseases caused
by hereditary or acquired RyR1 malfunction.
Keywords: skeletal muscle, excitation-contraction coupling, sarcolemma, sarcoplasmic reticulum, Ca2+ release
channel, ryanodine receptor type 1, RyR1-related mutations, RyR1 dysfunction and disease
INTRODUCTION TO EXCITATION-CONTRACTION COUPLING
The process of voluntary muscle contraction starts with the intention to move, as generated in the
frontal lobe and motor cortical regions of the brain (Dum and Strick, 2002). These cortical areas
extend neuronal projections to the spinal cord (Rizzolatti and Luppino, 2001). The motoneurons’
dendritic arbors and cell bodies serve as the final processing station for corticospinal signals;
their axons then leave the spinal cord forming motor nerves, which subsequently deviate from
the nerve as it finally approaches the target muscle. Single axons then branch to innervate and
control a fixed number of muscle fibers, collectively known as the motor unit. The action potential
ultimately reaches the neuromuscular junction, a specialized synapse between the motoneuron
and its target muscle fiber, where acetylcholine (ACh) is released from the presynaptic membrane
(Hubbard, 1973; Katz, 1996) and binds to postsynaptic ACh nicotinic receptors (Marques et al.,
2000; Wu et al., 2010). Activation of ACh nicotinic receptors induces an end-plate potential and
this electrical impulse continues along the muscle fiber as an action potential. The process by
which this electrical impulse of muscle fibers (aka myofibers) initiates muscle contraction is termed
excitation-contraction coupling (ECC; Sandow, 1952).
Each action potential is propagated both axially along the myofiber and radially into the
myofiber (Figures 1A,B; Huxley and Taylor, 1958; Adrian et al., 1969; Adrian and Peachey, 1973).
The action potential depolarization is generated primarily by current through Nav1.4 sodium
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FIGURE 1 | Muscle structure and function: from the myofiber to RyR1 Ca2+ release complex. (A) Morphology of skeletal muscle fibers. Top Panel:
Transmitted light image of isolated muscle fibers from mouse flexor digitorum brevis via enzymatic dissociation; image was acquired using low magnification. Lower
Panel: A higher magnification image of the fiber segment enclosed by a dashed rectangle. Note the characteristic striated pattern of muscle fibers, which results from
highly organized array between sarcolemma, sarcoplasmic reticulum (SR), contractile elements and cytoarchitecture of the fibers. (B) Structure of the triad. In most
cases the myoplasmic side of the junctional SR is closely apposed either to T-tubule or surface membrane, forming different junctions called dyads, triads, or
peripheral coupling. The cartoon depicts a longitudinal section of the T-tubule axis, but a cross-section of the triad, a specialized array formed by the T-tubule and two
segments of the terminal junctional SR (aka the terminal cisternae). The T-tubules are invaginations of the sarcolemma that propagate the action potential and possess
the Cav1.1 voltage sensors that initiate the early steps of ECC. The voltage dependent Ca2+ channels, Cav1.1 (blue, aka DHPR), are positioned in both the T-tubule
and sarcolemma. The SR Ca2+ release channel, RyR1 (brown), is located on the junctional domain of the SR surface, facing the T-tubules, and is also known as the
junctional SR face membrane. Some RyRs may be present in adjacent parajunctional SR domains (orange). (C) Detailed architecture of the Cav1.1-RyR1 complex
shown in (B). About half of the total RyR1s do not associate with Cav1.1, resulting in an alternating pattern of “free” and Cav1.1-associated RyR1s. Note: In addition
to Cav1.1 and RyR1, many other proteins form part of the T-tubule- junctional SR complex (e.g., FKPB12, triadin, junctin, Casq1) and are not shown here. Panels
(B,C) are based on references: (Franzini-Armstrong and Porter, 1964; Franzini-Armstrong and Nunzi, 1983; Block et al., 1988; Franzini-Armstrong and Jorgensen,
1994; Franzini-Armstrong and Kish, 1995; Franzini-Armstrong and Protasi, 1997).
channels, the skeletal muscle voltage-gated sodium channel,
localized at the sarcolemma and through the transverse (T)-
tubule system of the myofiber (Figure 1B). T-tubules are
extensions of the sarcolemma that form a branched network
of radial invaginations of the surface membrane, penetrating
the myofiber to surround each myofibril, this occurs at the
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level of the A-I junction in each mammalian muscle sarcomere
(Adrian et al., 1970; Adrian and Marshall, 1977; Jurkat-Rott
et al., 2006). Depolarization of the T-tubule membrane induces
conformational changes in the T-tubule EC coupling voltage
sensor, the voltage-gated Ca2+ channel (Cav1.1; Figures 1B,C),
also known as the dihydropyridine receptor (DHPR; Rios and
Brum, 1987). In skeletal muscle, the DHPR is mechanically
coupled to the ryanodine receptor Ca2+ release channel type 1
(RyR1), which in contrast to the DHPR, rests in the sarcoplasmic
reticulum (SR; Figures 1B,C; Takeshima et al., 1989). The
Cav1.1-coupled RyR1 channels mediate, by a mechanism poorly
understood, rapid Ca2+ release from the SR into the cytosol in
response to the muscle action potential in the T-tubules, leading
to Ca2+ binding to thin filament troponin C and activation for
contraction (Schneider and Chandler, 1973; Block et al., 1988).
The activity of RyR1 is also regulated by Ca2+ (Meissner et al.,
1986; Endo, 2006), therefore Ca2+ released through molecularly
coupled RyR1 could activate Cav1.1-uncoupled RyR1s in close
proximity by a process known as Ca2+-induced Ca2+ release
(CICR; Endo, 2009) or via allosteric interactions between
adjacent RyR1s (Marx et al., 1998). The contribution of CICR
and allosteric coupled RyR1 gating during physiological skeletal
muscle activity remains controversial (Endo, 2009; Figueroa
et al., 2012). In the process of muscle activation, the sequence
of communication from Cav1.1 to RyR is called orthograde
signaling (Beam and Horowicz, 2004). The opposite sequence
of coupling, from RyR1 to Cav1.1 is known as retrograde
signaling (Nakai et al., 1996; Dirksen, 2002). Retrograde signaling
causes an enhancement in the activity of Cav1.1 in response
to the activation of RyR1 induced by Cav1.1 (Dirksen, 2002).
Membrane depolarization of the sarcolemma and T-tubule
system also activates Ca2+ influx through Cav1.1 (Stanfield, 1977;
Sanchez and Stefani, 1978). While this Cav1.1-dependent Ca2+
flux appears to be important for activation of Ca2+-dependent
signaling pathways, SR refilling during sustained activity and
modulation of energy utilization, it is not essential for active ECC
in adult skeletal muscle (Georgiou et al., 2015; Lee et al., 2015).
Ca2+ release is subsequently decreased during depolarization
by Ca2+-induced inactivation of RyR1, a negative feedback
mechanism, and eventually terminated by membrane
repolarization, which drives the return of Cav1.1 to a closed
and resting state by reversing the activation of the Cav1.1
voltage sensor (Schneider and Hernández-Ochoa, 2012). Muscle
relaxation then results from Ca2+ removal from myoplasm via
transport back to the SR primarily via sarcoplasmic-endoplasmic
reticulum ATPase (SERCA), the SR ATP-dependent Ca2+ pump
(Hasselbach, 1964; Schneider and Simon, 1988; Schneider and
Hernández-Ochoa, 2012). These processes prevent continuous
Ca2+ influx, restore the initial resting state, and allow the ECC
cycle to be repeated (Melzer et al., 1995; Berchtold et al., 2000).
RYR1 FUNCTION, STRUCTURE, AND
REGULATION
The function of skeletal muscle relies on the movement of
Ca2+ out of and back into the storage compartment, the SR
(Green and MacLennan, 2002). Release of Ca2+ from the SR,
via RyR1, results in muscle contraction. The RyR1 is a ∼2.3
MDa assembly of four identical subunits (each subunit is formed
by ∼5000 amino acids; Imagawa et al., 1987; Inui et al., 1987).
The subunit topology consists of a pore region formed by six
transmembrane helices located within the C-terminal region,
representing ca. 20% of total protein. The N-terminal region
is a large cytoplasmic region that represents 80% of the total
protein, known as the foot region (see Figure 2; Radermacher
et al., 1992; Serysheva et al., 1995, 2005, 2008; Ludtke et al.,
2005; Samso et al., 2005, 2006, 2009; Yan et al., 2015; Zalk et al.,
2015). The myoplasmic portion of the channel (280 Å × 280
Å × 120 Å) is continuous with the transmembrane region (120
Å × 120 Å × 60 Å; Figure 2). The SR transmembranal region
forms the Ca2+ release channel (Ludtke et al., 2005; Samso et al.,
2005, 2006; Serysheva et al., 2005; Yan et al., 2015; Zalk et al.,
2015).
RyR1s are organized in regular checkered arrays within the
terminal cisternae of the junctional SR (Franzini-Armstrong
and Nunzi, 1983; Franzini-Armstrong et al., 1998). Cav1.1
channels are clustered in groups of four (or tetrads) in the T-
tubule membrane portion that is in the vicinity of junctional
SR (Block et al., 1988). Cav1.1 channels in the tetrad assume
a coordinated location relative to the four subunits of the
apposed RyR1 (see Figure 1C; Block et al., 1988), however these
interactions only occur at every other RyR1. This results in half
of RyR1s that are not associated with Cav1.1 (uncoupled RyR1;
Franzini-Armstrong and Kish, 1995). The location of coupled
and uncoupled RyR1 is dictated by the organization of the Cav1.1
molecules in the apposed T-tubule membrane, and thus mark
a “checkerboard” array of coupled and uncoupled RyR1s that
follows the Cav1.1 lattice organization (see Figure 1; Yin and Lai,
2000). Depolarization-induced activation of RyR1 is mediated
via direct interactions with T-tubule voltage-sensitive Cav1.1
channels positioned in the abutted T-tubule membrane (Rios and
Brum, 1987; Nakai et al., 1998a,b; Protasi et al., 2002). Exactly
where and how these T-tubule voltage-dependent interactions
between Cav1.1 and RyR1 occur remains elusive.
The RyR1 components, including SR luminal segments,
transmembrane domains, large cytosolic domains, and
interaction with the Cav1.1 channels, allow the RyR1s to be
modulated and fine-tuned by multiple mechanisms (Serysheva
et al., 2005; Samso et al., 2006; Yan et al., 2015; Zalk et al.,
2015). Intracellular ions and components (e.g., cytosolic Ca2+,
ATP, Mg2+, SR Ca2+ concentration, Meissner et al., 1986;
Fill and Copello, 2002) and post-translational modifications
(e.g., oxidation, S-nitrosylation, phosphorylation, Sonnleitner
et al., 1997; Marengo et al., 1998; Eu et al., 2000; Sun et al.,
2001; Fill and Copello, 2002; Aracena et al., 2003; Hidalgo
et al., 2005) all regulate the activity of the RyR1. The RyR1
also interacts with numerous SR intraluminal proteins (e.g.,
calsequestrin, junctin, triadin; MacLennan and Wong, 1971;
Brillantes et al., 1994; Glover et al., 2002; Beard et al., 2009;
Treves et al., 2009), cytosolic proteins (e.g., FKBP12, calmodulin
(CaM), S100A1; Fuentes et al., 1994; Buratti et al., 1995; Ikemoto
et al., 1995; Tripathy et al., 1995; Ahern et al., 1997; Samso
and Wagenknecht, 2002; Chelu et al., 2004; Samso et al., 2006;
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FIGURE 2 | Cav1.1-RyR1 complex: molecular details. Shown is a reconstruction from cryo-electron microscopy of the mammalian RyR1 at 4.8 Å illustrating the
different regions. This includes the large myoplasmic segment and its multiple cavities and processes, and the SR transmembranal segment, which forms the Ca2+
conduction pathway (Electron microscopy data bank entry 6106, Zalk et al., 2015). The above properties allow the RyR1 to interact with multiple SR luminal and
cytosolic proteins. Several 3-D structures of proteins interacting with RyR1, as well as their relative locations, are also shown. EMData bank PDB entry and references:
calsequestrin-1 (Casq1) polymer (3UOM, Sanchez et al., 2012), FKBP-12 (1D6O, Burkhard et al., 2000), S100A1 (2K2F; Wright et al., 2008), calmodulin (CaM; 1CLL,
Chattopadhyaya et al., 1992), Cav1.1α subunit (4MS2, Tang et al., 2014; Hu et al., 2015), and Cav1.1 β subunit (1T0J, Van Petegem et al., 2004; Hu et al., 2015); only
two alpha and two beta subunits are shown. In the muscle fiber Cav1.1 channels are clustered in groups of four (or tetrads) in the T-tubules. Cav1.1 channels in the
tetrad interact with the four subunits of the RyR1, one Cav1.1 per each RyR1 subunit. All structures were generated using UCSF Chimera (Pettersen et al., 2004).
Prosser et al., 2008; Wright et al., 2009) and domains of the
Cav1.1 α and β subunits (Nakai et al., 1994, 1998a,b; Gregg et al.,
1996; Beurg et al., 1999a,b; Sheridan et al., 2006), located in the
T-tubule and myoplasm, respectively. Further details on RyR1
structure-function relationship can be found in recent literature
(Van Petegem et al., 2004; Lanner et al., 2010; Lanner, 2012; Van
Petegem, 2015).
Given the critical role of RyR1s for skeletal muscle ECC,
mutations in the RyR1s and the resulting Ca2+ dysregulation are
a primary cause of several hereditary skeletal muscle myopathies.
In addition, indirect or secondary RyR1 malfunction is also
present in other myopathies not related to RyR1 mutations.
Both congenital and acquired myopathies are a heterogeneous
group of skeletal muscle weakness disorders caused by mutations
or dysfunction in different structural, contractile, or regulatory
muscle proteins. Several reviews have been published on various
aspects of skeletal muscle myopathies (Betzenhauser and Marks,
2010; Lanner et al., 2010; Maclennan and Zvaritch, 2011; Lanner,
2012; Dowling et al., 2014; Vallejo-Illarramendi et al., 2014). Here
we focus on primary RyR1 mutation-related myopathies, as well
as considering Duchenne muscular dystrophy (DMD), a disease
with a secondary involvement of RyR1.
RYR1 PRIMARY MUTATION-RELATED
MYOPATHIES
General Implication of RyR1 Disease
Mutations
Mutations in RyR1 can be grouped into four general categories
according to their effects on RyR1 function (Treves et al.,
2008; Loy et al., 2011). The first category of RyR1 mutations
cause a higher probability of activation of RyR1 by muscle
fiber electrical depolarization or by RyR1 activators, and are
manifested in the malignant hyperthermia (MH) phenotype.
In the second category, RyR1 mutations cause leaky channels
leading to Ca2+ dysregulation and depletion of Ca2+ from SR,
and result in central core disease (CCD). The third category of
RyR1 mutations causes deficits on the Cav1.1-mediated voltage
dependent activation of SR Ca2+ release, a process also known
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as excitation-contraction uncoupling, and result in certain forms
of CCD. The fourth category of mutations are a consequence of
wild type allele silencing, a process that mimics homozygosity,
and causes a decrease of RyR1 channel expression, resulting in
multi-minicore disease (MmD.) In the majority of these primary
myopathies, mutations in the RyR1, result in gain of function
and Ca2+ dysregulation. The consequences of these mutations
on RyR1’s activity are compound; RYR1-related MH and CCD
produce hypersensitive and/or leaky RyR1 channels (Tong et al.,
1997; Lynch et al., 1999; Yang et al., 2007). Some CCD present
excitation-contraction uncoupling (Avila et al., 2001; Dirksen
and Avila, 2002; Kraeva et al., 2013) or exhibit RyR1 leaky
channels (Dirksen and Avila, 2002; Zvaritch et al., 2009), but
the exact mechanisms are unclear (Dowling et al., 2014). Many
RyR1 mutations are not so obviously correlated with alterations
in Ca2+ release (Maclennan and Zvaritch, 2011; Dowling et al.,
2014), and their pathogenicity is less clear.
Malignant Hyperthermia
Malignant hyperthermia is a subclinical, autosomal dominant,
pharmacogenetic disorder that causes skeletal muscle
intracellular Ca2+ dysregulation, characterized by a sudden
and potentially fatal hypermetabolic adverse response to volatile
anesthetics (e.g., isoflurane, sevoflurane, halothane) and/or the
depolarizing muscle relaxant, succinylcholine (Denborough
et al., 1962; Rosenberg et al., 2007; Maclennan and Zvaritch,
2011). MH manifests mostly in individuals carrying mutations
in RyR1 (MacLennan et al., 1990), but some Cav1.1 mutations
are also linked to MH (Rosenberg et al., 2007; Maclennan and
Zvaritch, 2011). When MH-susceptible individuals are expose
to trigger agent(s) (Denborough et al., 1962), they develop
hypercarbia, tachycardia, muscle rigidity (some cases), rapid
and severe hyperthermia (e.g., core body temperatures of 43◦C),
rhabdomyolysis and metabolic acidosis (Rosenberg et al., 2007;
Larach et al., 2010; Maclennan and Zvaritch, 2011). MH may
occur at any time during the anesthesia and in the postoperative
period (Rosenberg et al., 2007). MH episodes account for many
anesthetic-induced deaths in the operating room in otherwise
healthy individuals (Maclennan and Zvaritch, 2011; Rosenberg
et al., 2007). Untreated, episodes of MH are lethal in 90% of the
cases. Consequences of MH include damage to brain, kidney
and muscle tissues. In United States, MH complicates 1 out
of 100,000 surgeries in adults and 1 out of 30,000 surgeries in
children (Malignant Hyperthermia Association of United Sates;
http://www.mhaus.org).
Different regions of RyR1 are targets ofMH causingmutations
(Manning et al., 1998; Barone et al., 1999; Brandt et al., 1999;
Chamley et al., 2000; Rueffert et al., 2004; Betzenhauser and
Marks, 2010). Dominant RyR1 mutations are the leading cause
of MH. Studies on the Ca2+ conducting properties of RyR1
channels containing MH mutations expressed in myotubes
(Dietze et al., 2000; Yang et al., 2003; Chelu et al., 2006;
Bannister et al., 2010) and mature muscle fibers (Owen et al.,
1997; Andronache et al., 2009), as well as animal models
of MH (Mickelson and Louis, 1996; Chelu et al., 2006) and
affected humans (Denborough et al., 1962; Melzer and Dietze,
2001), have concluded that MH mutations cause a channel
gain of function, characterized by hyper-activation and hyper-
sensitization to pharmacological activators. Current treatment
includes immediate suspension of the triggering agent(s),
cooling measures (hypothermic blankets), and 100% oxygen
administration, as well as prompt treatment with dantrolene, a
drug that acts as Ca2+ release inhibitor (Hainaut and Desmedt,
1974; Kobayashi et al., 2005), presumably acting on RyR1
(Fruen et al., 1997) and that requires of CaM for its effects
(Oo et al., 2015). Ca2+ entry, via non-specific sarcolemmal
channels, contributes to the pathogenesis of MH episodes (Eltit
et al., 2013). Dantrolene also attenuates elevations on resting
[Ca2+] that is dependent on Ca2+ entry (Cherednichenko
et al., 2008; Eltit et al., 2013). Because dantrolene appears to
suppress Ca2+ release and Ca2+ entry, it is not surprising
that dantrolene could affect other proteins involved in ECC.
Regardless of the action(s), dantrolene is currently the only
available pharmacological treatment for MH (Mickelson and
Louis, 1996; Lyfenko et al., 2004; Litman and Rosenberg, 2005)
and reduces MH mortality significantly (Rosenberg et al., 2007;
Schneiderbanger et al., 2014). Susceptibility to MH attacks can
be detected prior to surgery using in-vitro assays that measure
muscle contractile responses and halothane or caffeine sensitivity
assays using muscle biopsies from individuals at risk or with
family history of enhanced sensitivity to these agents, or in
known individuals with MH-mutations (Rosenberg et al., 2007;
Schneiderbanger et al., 2014).
The RyR1-Related Congenital Myopathies:
Central Core Disease and Multi-Minicore
Disease
These RyR1-related congenital myopathies are rare muscle
disorders (incidence of 6 out of 100,000 births) that exhibit
either autosomal dominant or recessive inheritance patterns.
They are typically manifested at birth, or during childhood,
and are characterized by generalized muscle weakness and low
muscle tone (Magee and Shy, 1956; Shuaib et al., 1987; Jungbluth,
2007a,b). There are many forms of congenital myopathy, each
defined by a specific pattern of histological abnormalities,
and clinical course severity (Jungbluth, 2007a,b; Nance et al.,
2012). Most individuals with congenital myopathies follow a
relatively stable clinical course. Typically these patients present
with ophthalmoparesis (eye muscle weakness), myasthenia
(muscle weakness), and abnormal movement due to joint
contractures. Patients may develop dysfunction of respiratory
muscles, scoliosis, or difficulty swallowing (dysphagia; Jungbluth,
2007a,b). In comparison to MH episodes, the symptoms in CCD
are not elicited by an external trigger. Currently, there is no cure
for CCD; the treatment is supportive and aimed to maintain
mobility and independence (Jungbluth, 2007a,b). At the cellular
level, core myopathies are characterized by regions in muscle
fibers devoid of mitochondria that appear as “cores” on oxidative
stains (Dubowitz and Pearse, 1960; Gonatas et al., 1965). In CCD,
cores are large and extend longitudinally. In MmD, the cores are
short and vary in size and location (Sewry et al., 2002). Mutations
in RYR1 are an important cause/factor of several forms of
congenital myopathies, >60 mutations in RyR1 are linked to
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CCD (Quane et al., 1993; Zhang et al., 1993; Treves et al., 2008).
Studies on the Ca2+ conducting properties of RyR1 channels
containing CCD mutations expressed in myotubes concluded
that CCD mutations cause SR Ca2+ leak due to hyperactive
RyR1 channels (Tong et al., 1997; Lynch et al., 1999) or ECC
uncoupling (Avila et al., 2001; Dirksen and Avila, 2002), and link
these events to the development of cores and muscle weakness.
The specific underlying process that causes the core formation is
still unknown.
Secondary Involvement of RyR1 in Muscle
Duchenne Muscular Dystrophy
DMD, a devastating and lethal inherited X-linked neuromuscular
disease, is one of the most common genetic diseases (Mah
et al., 2014). DMD almost exclusively affects boys, resulting
in muscular dysfunction and premature death (Emery, 2002).
The primary defect in DMD is the lack of dystrophin, a
427 kDa cytoskeletal protein that structurally links the contractile
machinery to the dystrophin-glycoprotein complex and to
components of the extracellular matrix (Hoffman et al., 1987;
Campbell, 1995; Blake et al., 2002). Lack of dystrophin results in
myofibers structurally defective and prone to damage. However,
the absence of dystrophin alone cannot immediately account for
the intricate clinical course and pathogenic mechanisms seen
in DMD (Berchtold et al., 2000; Allen et al., 2010; Allen and
Whitehead, 2011), and multiple hypotheses have been proposed
as intervening events to explain the pathological alterations
observed in DMD (Florence et al., 1985; McArdle et al., 1995;
Tutdibi et al., 1999; Berchtold et al., 2000; Lovering et al., 2009a,
2013; Allen et al., 2010; Allen and Whitehead, 2011; Pratt et al.,
2013, 2015; Xu et al., 2012; Mazala et al., 2015).
Regarding the involvement of RyR1 in muscular dystrophy, it
is well established that dystrophin-deficient myofibers, especially
those with malformed morphology (Lovering et al., 2009b;
Hernández-Ochoa et al., 2015), have deficits in ECC (Collet
et al., 1999; Woods et al., 2004, 2005; Hollingworth et al.,
2008; Lovering et al., 2009b; Hernández-Ochoa et al., 2015),
which is manifested as altered action potential-elicited RyR1
Ca2+ release from the SR (Woods et al., 2004). Several
proposed mechanisms might explain the differences in ECC
found between healthy and dystrophin-deficient myofibers,
among them are alterations in the expression levels of
Cav1.1 and RyR1, changes in Ca2+ buffering capacity (Doran
et al., 2004; Dowling et al., 2004), dysfunction of membrane
channels (Yeung et al., 2005), and differences in levels
of ROS (Whitehead et al., 2010; Allen and Whitehead,
2011).
There is also evidence that increased S-nitrosylation of
RyR1 in dystrophin deficient muscles, leads to FKBP12-RYR1
destabilization and increases RyR1 Ca2+ leak (channel opening
at rest; Bellinger et al., 2009). It is likely that these modifications
occur at intermediate or end stages of the transition from normal
to apoptotic/necrotic fiber, where RyR1 leak will worsen Ca2+
dysregulation.
Thus, DMD appears to affect the activity of the RyR1 in two
opposite ways: (1) First, in early stages of myofiber damage, or
in pre-apoptotic phases, the overall function of RyR1 is reduced,
leading to depressed action potential-induced RyR1 Ca2+ release
(Collet et al., 1999; Woods et al., 2004, 2005; Hollingworth
et al., 2008; Lovering et al., 2009b; Hernández-Ochoa et al.,
2015). Since the magnitude of myofiber contraction and
consequent force production are finely controlled by intracellular
Ca2+ release (Chin, 2010), in DMD a gradual reduction
RyR1 Ca2+ release contributes to the development of muscle
weakness. (2) In advanced stages of the disease, RyR1 becomes
hypersensitive to intracellular Ca2+ activation. Functional and
post-translational modifications in RyR1 contribute to altered
Ca2+ homeostasis in dystrophin-deficient muscles (Bellinger
et al., 2009; Allen et al., 2010; Allen and Whitehead, 2011).
Age-dependent S-nitrosylation of the RyR1 complex causes
depletion of FKBP12 from the RyR1, resulting in a remodeling
of the RyR1 channel complex, which in turn elicits intracellular
SR Ca2+ leak and impaired contractility (Bellinger et al.,
2009). The concurrent increased Ca2+ influx across the plasma
membrane, due to inherent membrane fragility and consequent
membrane damage, is thought to cause further membrane
damage via multiple mechanisms including calpain activation
(Berchtold et al., 2000; Allen et al., 2010; Allen and Whitehead,
2011).
Despite recent advances in understanding DMD, targeted
pharmacological treatment for DMD is nearly non-existent
(Andersson and Marks, 2010). In this regard, a new class of
small-molecules “Rycals,” which reduce Ca2+ leak by stabilizing
the FKBP12-RyR1 interaction, have been shown to improve
contractility in skeletal muscle in the mdx mouse model of
DMD (Bellinger et al., 2009). Rycal ARM210, has potential as
a treatment for DMD; it has completed preclinical efficacy and
safety studies, and has been selected for advancement to clinical
development (Muscle Dystrophy Association; https://www.mda.
org).
Given the critical role of RyR1 in Ca2+ release and Ca2+
signaling, any disease condition that affects RyR1 function
via post-translational modifications could affect ECC, Ca2+-
dependent metabolic and genetic programs, and untimely
impinge on skeletal muscle function. In support of this view,
recent reports have shown post-transcriptional alterations of
RyR1 inmuscle weakness related to arthritis (Yamada et al., 2016)
and cancer (Waning et al., 2015) in murine models.
CONCLUSIONS
Many skeletal myopathies result from intracellular Ca2+
dysregulation and alterations in a myriad of Ca2+ dependent
processes, including muscle contraction, signaling pathways,
metabolism and gene regulation. Reduced SR Ca2+ release
translates to deficient muscle contraction and muscle weakness.
Sustained increases in cytoplasmic [Ca2+] or decreased SR
intraluminal Ca2+ are key pathological events leading to muscle
contractures (i.e., in MH episodes), apoptosis and necrotic
muscle degeneration (i.e., dystrophinopathies; Maclennan and
Zvaritch, 2011). In addition, many key channels, transporters,
Ca2+ buffers and modulators of Ca2+ signaling contribute to
abnormal Ca2+ handling in several muscle myopathies. Skeletal
muscle research will continue to expand our understanding
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of these myopathies, as well as the function and dysfunction
of the RyR1. Despite that the current near-atomic resolution
RyR1 reconstructions are in the 4.8–3.8 Å range, more detailed
RyR1 images are still needed, as well as specifics about
RyR1’s interactions with Cav1.1 and many other auxiliary and
modulatory proteins (Van Petegem, 2015). Also, more in-
depth function-structure studies (from molecular biophysics to
systems physiology), increased sensitivity of structural biology
methods and likely the development of new biochemical and
physiological assays, are required. These studies will propel our
knowledge about RyR1 function and dysfunction, and facilitate
the development of new RyR1-selective drugs for RyR1-related
myopathies.
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